0930 Pfizer CStone
BioCentury & Getty Images

Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

The pharma believes sugemalimab could be a best-in-class checkpoint inhibitor

The pharma believes sugemalimab could be a best-in-class checkpoint inhibitor.

Sep 30, 2020 | 9:56 PM GMT

A deal giving Pfizer local rights to CStone’s PD-L1 inhibitor will add at least $200 million to the Suzhou-based biotech’s balance sheet

Read the full 680 word article

How to gain access

Continue reading with a
two-week free trial.